| Acimtamig | AFM-13 | Phase 2 Clinical | The University Of Texas MD Anderson Cancer Center | Hodgkin Disease; Lymphoma, B-Cell; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell, Peripheral; Mycosis Fungoides | 詳細 |
| ATLCAR.CD30 cells (UNC Lineberger Comprehensive Cancer Center) | | Phase 2 Clinical | Unc Lineberger Comprehensive Cancer Center | Hodgkin Disease; Immune System Diseases; Immunoproliferative Disorders; Lymphatic Diseases; Lymphoma; Lymphoma, Non-Hodgkin; Lymphoma, Primary Cutaneous Anaplastic Large Cell; Lymphoma, T-Cell, Cutaneous; Lymphoma, T-Cell, Peripheral; Lymphomatoid Papulosis; Lymphoproliferative Disorders; Mycosis Fungoides; Neoplasms; Neoplasms, Germ Cell and Embryonal; Sezary Syndrome | 詳細 |
| Autologous CD30+ CAR T Cells therapy(New York Medical College) | | Phase 2 Clinical | New York Medical College, University Of North Carolina At Chapel Hill | | 詳細 |
| Itezocabtagene autoleucel | TT-11; TT11 | Phase 2 Clinical | Tessa Therapeutics Ltd | Hodgkin Disease; Lymphoma, Extranodal NK-T-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Large-Cell, Anaplastic; Lymphoma, T-Cell, Peripheral; Primary mediastinal B cell lymphoma | 詳細 |
| BRD-01 | BRD-01 | Phase 2 Clinical | Wuhan BioRaid Biotechnology Co Ltd | Hematologic Neoplasms; Hodgkin Disease | 詳細 |
| PRA-052 | PRA-052; MK-8690; PR-600 | Phase 2 Clinical | Prometheus Biosciences Inc | | 詳細 |
| HSP-CAR-30 | HSP-CAR-30 | Phase 2 Clinical | Fundació Institut De Recerca De L | Hodgkin Disease; Lymphoma, T-Cell | 詳細 |
| Anti-CD30 CAR T-cell therapy (General Hospital of the People's Liberation Army/Cellular Biomedicine) | CAR30-NKT; CBM-C30.1; CD30ScFv-CD8-CD137-CD3zeta | Phase 2 Clinical | Pla General Hospital | | 詳細 |
| Anti-CD30 chimeric antigen receptor T cell therapy (Immune cell) | | Phase 1 Clinical | Immune Cell Inc | Hodgkin Disease; Lymphoma, Large-Cell, Anaplastic | 詳細 |
| CD30.CAR-EBVST cell therapy (Baylor College of Medicine) | TT-11X | Phase 1 Clinical | Baylor College Of Medicine, Tessa Therapeutics Ltd | Hodgkin Disease; Lymphoma, Extranodal NK-T-Cell; Lymphoma, Large B-Cell, Diffuse | 詳細 |
| EBV-specific-CAR.CD30 | EBV-specific-CAR.CD30; CAR.CD30 EBV-specific-CTLs | Phase 1 Clinical | Baylor College Of Medicine, Methodist Hospital System, Texas Children'S Hospital | Hodgkin Disease; Lymphoma, Non-Hodgkin | 詳細 |
| Anti-CD30 CAR T-cell therapy (Wuhan Bio-Raid) | | Phase 1 Clinical | Wuhan BioRaid Biotechnology Co Ltd | Angioimmunoblastic T-cell Lymphoma; Hematologic Neoplasms; Hodgkin Disease; Leukemia-Lymphoma, Adult T-Cell; Lymphoma, Extranodal NK-T-Cell; Lymphoma, Large-Cell, Anaplastic; Lymphoma, T-Cell, Peripheral | 詳細 |
| B-0069 (Shanghai Pharmaceuticals Holding) | F0002-ADC; B-006(SCP) | Phase 1 Clinical | Shanghai Pharmaceuticals Holding Co Ltd | Hematologic Neoplasms; Hodgkin Disease; Lymphoma, Large-Cell, Anaplastic; Lymphoma, T-Cell, Peripheral | 詳細 |
| CD30.CAR | H-27721; CD30.CAR | Phase 1 Clinical | Baylor College Of Medicine | Hodgkin Disease; Lymphoma, B-Cell; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell, Peripheral | 詳細 |
| CD30 CAR-T Cells therapy (Unicar-Therapy Bio-Medicine Technology) | U29 | Phase 1 Clinical | Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd | | 詳細 |
| ATLCAR.CD30.CCR4 | | Phase 1 Clinical | Unc Lineberger Comprehensive Cancer Center | Immune System Diseases; Immunoproliferative Disorders; Lymphatic Diseases; Lymphoma; Lymphoma, Primary Cutaneous Anaplastic Large Cell; Lymphoma, T-Cell, Cutaneous; Lymphomatoid Papulosis; Lymphoproliferative Disorders; Mycosis Fungoides; Neoplasms; Sezary Syndrome | 詳細 |
| Chimeric antigen receptor gene modified T cells therapy (Qilu Cell Therapy Engineering&Technology) | | Phase 1 Clinical | Shandong Qilu Cell Treapy Engineering&Technology Co Ltd | Lymphoma; Lymphoma, B-Cell; Lymphoma, T-Cell | 詳細 |
| Anti-CD20/CD30-CAR-T Cell therapy(Shanghai Tongji Hospital) | | Phase 1 Clinical | Shanghai Tongji Hospital | Leukemia, B-Cell; Lymphoma; Lymphoma, B-Cell | 詳細 |
| CD30-Targeted LCAR-HL30 Cells therapy(Legend Biotechnology) | | Phase 1 Clinical | | Hodgkin Disease; Lymphoma, Large-Cell, Anaplastic | 詳細 |
| SGN-35C | SGN-35C; PF-08046044 | Phase 1 Clinical | Seagen Inc | Hodgkin Disease; Lymphoma; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Large-Cell, Anaplastic; Lymphoma, T-Cell, Peripheral | 詳細 |
| Anti-CD30 CAR T-cell therapy | | Phase 1 Clinical | Minghui (Nanjing) Gene Biotechnology Co Ltd | Hodgkin Disease; Lymphoma, Large-Cell, Anaplastic | 詳細 |
| CD30 biAb-AATC(The Medical College Of Wisconsin Nonprofit) | | Phase 1 Clinical | The Medical College Of Wisconsin Nonprofit | Hodgkin Disease; Leukemia; Lymphoma; Lymphoma, B-Cell; Lymphoma, Large-Cell, Anaplastic; Lymphoma, T-Cell, Cutaneous | 詳細 |
| Anti-CD30 CAR-T cell therapy (National Cancer Institute) | Hu30-CD28z | Phase 1 Clinical | National Cancer Institute | Enteropathy-Associated T-Cell Lymphoma; Lymphoma; Lymphoma, Extranodal NK-T-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Large-Cell, Anaplastic; Lymphoma, T-Cell, Peripheral | 詳細 |
| SGN-CD30C | SGN-CD30C | Phase 1 Clinical | Seattle Genetics Inc | | 詳細 |
| Anti-CD30 chimeric antigen receptor T cell therapy (Yake Biotechnology) | | Clinical | Shanghai YaKe Biotechnology Co Ltd | | 詳細 |